5mg tirzepatide injectable peptide Lilly releases Zepbound® (tirzepatide) single-dose

doi: 10.1093/jn/132.8.2241

Topline The use of GLP-1 medications like semaglutide for weight loss has increased twofold over the past decade, but declined in use among those with type 2 diabetes, according to a new study, and the researchers warn the resulting and ongoing drug shortage may limit the access people with diabetes have to the drugs

One big thing: In the study above, participants were divided into different groups that changed their diets, added exercise, both, or neither

Total costs range from $444 to $594 per month, which is higher than IVIM compounded option but provides brand-name, FDA-approved medication

Judge Karen Marston is currently weighing issues of preemption and general causation before moving forward with bellwether trials

Effects of six months of combined aerobic and resistance training for elderly patients with a long history of type 2 diabetes